C4 Therapeutics Inc.
04/10/2026 | Press release | Distributed by Public on 04/10/2026 05:17
Amendments to Bylaws (Form 8-K)
Item 5.03 Amendments to Articles of Incorporation or By-laws; Change in Fiscal Year.
On April 9, 2026, the Board of Directors (the "Board") of C4 Therapeutics, Inc. (the "Company") approved an amendment to the Company's second amended and restated by-laws (the "By-laws Amendment"), effective immediately, to designate the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum. The Board approved the By-laws Amendment in response to recent amendments to the Generate Corporation Law of the State of Delaware regarding such forum selection provisions.
The foregoing description of the By-laws Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
C4 Therapeutics Inc. published this content on April 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 10, 2026 at 11:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]